{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T08:33:39Z","timestamp":1790757219940,"version":"4.1.0"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,1,17]],"date-time":"2018-01-17T00:00:00Z","timestamp":1516147200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2018,1,17]],"date-time":"2018-01-17T00:00:00Z","timestamp":1516147200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81472480"],"award-info":[{"award-number":["81472480"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003399","name":"Shanghai Science and Technology Committee","doi-asserted-by":"crossref","award":["14140901201"],"award-info":[{"award-number":["14140901201"]}],"id":[{"id":"10.13039\/501100003399","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Cancer"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1186\/s12943-017-0746-0","type":"journal-article","created":{"date-parts":[[2018,1,17]],"date-time":"2018-01-17T14:21:04Z","timestamp":1516198864000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":108,"title":["microRNA-124 inhibits bone metastasis of breast cancer by repressing Interleukin-11"],"prefix":"10.1186","volume":"17","author":[{"given":"Wei-Luo","family":"Cai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen-Ding","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bo","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tian-Rui","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhen-Xi","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheng-Long","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heng-Yu","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan-Mei","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9759-2863","authenticated-orcid":false,"given":"Wang-Jun","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian-Ru","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,1,17]]},"reference":[{"key":"746_CR1","doi-asserted-by":"publisher","first-page":"87","DOI":"10.3322\/caac.21262","volume":"65","author":"LA Torre","year":"2015","unstructured":"Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin. 2015;65:87\u2013108.","journal-title":"CA Cancer J Clin"},{"key":"746_CR2","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/j.pharmthera.2016.03.003","volume":"161","author":"Z Li","year":"2016","unstructured":"Li Z, Kang Y. Emerging therapeutic targets in metastatic progression: a focus on breast cancer. Pharmacol Ther. 2016;161:79\u201396.","journal-title":"Pharmacol Ther"},{"key":"746_CR3","doi-asserted-by":"publisher","first-page":"2205","DOI":"10.1093\/annonc\/mdv284","volume":"26","author":"MF Ibrahim","year":"2015","unstructured":"Ibrahim MF, Mazzarello S, Shorr R, Vandermeer L, Jacobs C, Hilton J, et al. Should de-escalation of bone-targeting agents be standard of care for patients with bone metastases from breast cancer? A systematic review and meta-analysis. Ann Oncol. 2015;26:2205\u201313.","journal-title":"Ann Oncol"},{"key":"746_CR4","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1634\/theoncologist.2015-0377","volume":"21","author":"R Tanaka","year":"2016","unstructured":"Tanaka R, et al. Risk factors for developing skeletal-related events in breast cancer patients with bone metastases undergoing treatment with bone-modifying agents. Oncologist. 2016;21:508\u201313.","journal-title":"Oncologist"},{"key":"746_CR5","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1016\/j.cell.2011.09.024","volume":"147","author":"S Valastyan","year":"2011","unstructured":"Valastyan S, Weinberg RA. Tumor metastasis: molecular insights and evolving paradigms. Cell. 2011;147:275\u201392.","journal-title":"Cell"},{"key":"746_CR6","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1038\/nrc3055","volume":"11","author":"KN Weilbaecher","year":"2011","unstructured":"Weilbaecher KN, Guise TA, McCauley LK. Cancer to bone: a fatal attraction. Nat Rev Cancer. 2011;11:411\u201325.","journal-title":"Nat Rev Cancer"},{"key":"746_CR7","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1016\/j.pharmthera.2013.10.006","volume":"141","author":"M Esposito","year":"2014","unstructured":"Esposito M, Kang Y. Targeting tumor-stromal interactions in bone metastasis. Pharmacol Ther. 2014;141:222\u201333.","journal-title":"Pharmacol Ther"},{"key":"746_CR8","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1189\/jlb.0410226","volume":"88","author":"T Putoczki","year":"2010","unstructured":"Putoczki T, Ernst M. More than a sidekick: the IL-6 family cytokine IL-11 links inflammation to cancer. J Leukoc Biol. 2010;88:1109\u201317.","journal-title":"J Leukoc Biol"},{"key":"746_CR9","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1016\/j.cytogfr.2015.07.015","volume":"26","author":"CN Johnstone","year":"2015","unstructured":"Johnstone CN, Chand A, Putoczki TL, Ernst M. Emerging roles for IL-11 signaling in cancer development and progression: focus on breast cancer. Cytokine Growth Factor Rev. 2015;26:489\u201398.","journal-title":"Cytokine Growth Factor Rev"},{"key":"746_CR10","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1186\/1471-2407-13-16","volume":"13","author":"EM McCoy","year":"2013","unstructured":"McCoy EM, Hong H, Pruitt HC, Feng X. IL-11 produced by breast cancer cells augments osteoclastogenesis by sustaining the pool of osteoclast progenitor cells. BMC Cancer. 2013;13:16.","journal-title":"BMC Cancer"},{"key":"746_CR11","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1016\/j.tem.2014.03.014","volume":"25","author":"G Browne","year":"2014","unstructured":"Browne G, Taipaleenm\u00e4ki H, Stein GS, Stein JL, Lian JB. MicroRNAs in the control of metastatic bone disease. Trends Endocrinol Metab. 2014;25:320\u20137.","journal-title":"Trends Endocrinol Metab"},{"key":"746_CR12","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1155\/2013\/451248","volume":"35","author":"S Vimalraj","year":"2013","unstructured":"Vimalraj S, Miranda PJ, Ramyakrishna B, Selvamurugan N. Regulation of breast cancer and bone metastasis by microRNAs. Dis Markers. 2013;35:369\u201387.","journal-title":"Dis Markers"},{"key":"746_CR13","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1016\/S0960-9822(02)00809-6","volume":"12","author":"M Lagos-Quintana","year":"2002","unstructured":"Lagos-Quintana M, Rauhut R, Yalcin A, Meyer J, Lendeckel W, Tuschl T. Identification of tissue-specific microRNAs from mouse. Curr Biol. 2002;12:735\u20139.","journal-title":"Curr Biol"},{"key":"746_CR14","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1177\/1073858413497265","volume":"20","author":"M \u00c5kerblom","year":"2014","unstructured":"\u00c5kerblom M, Jakobsson J. MicroRNAs as neuronal fate determinants. Neuroscientist. 2014;20:235\u201342.","journal-title":"Neuroscientist"},{"key":"746_CR15","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1016\/j.expneurol.2011.11.035","volume":"235","author":"KC Sonntag","year":"2012","unstructured":"Sonntag KC, Woo TU, Krichevsky AM. Converging miRNA functions in diverse brain disorders: a case for miR-124 and miR-126. Exp Neurol. 2012;235:427\u201335.","journal-title":"Exp Neurol"},{"key":"746_CR16","doi-asserted-by":"publisher","first-page":"766","DOI":"10.1093\/carcin\/bgp250","volume":"31","author":"M Furuta","year":"2010","unstructured":"Furuta M, Kozaki KI, Tanaka S, Arii S, Imoto I, Inazawa J. miR-124 and miR-203 are epigenetically silenced tumor-suppressive microRNAs in hepatocellular carcinoma. Carcinogenesis. 2010;31:766\u201376.","journal-title":"Carcinogenesis"},{"key":"746_CR17","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1186\/1476-4598-9-167","volume":"9","author":"SM Wilting","year":"2010","unstructured":"Wilting SM, van Boerdonk RA, Henken FE, Meijer CJ, Diosdado B, Meijer GA, et al. Methylation-mediated silencing and tumour suppressive function of hsa-miR-124 in cervical cancer. Mol Cancer. 2010;9:167.","journal-title":"Mol Cancer"},{"key":"746_CR18","doi-asserted-by":"publisher","first-page":"E167","DOI":"10.1073\/pnas.1011540107","volume":"107","author":"I V\u00e1zquez","year":"2010","unstructured":"V\u00e1zquez I, Maicas M, Marcotegui N, Conchillo A, Guruceaga E, Roman-Gomez J, et al. Silencing of hsa-miR-124 by EVI1 in cell lines and patients with acute myeloid leukemia. Proc Natl Acad Sci U S A. 2010;107:E167\u20138.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"746_CR19","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1002\/path.4030","volume":"227","author":"J Xia","year":"2012","unstructured":"Xia J, Wu Z, Yu C, He W, Zheng H, He Y, et al. miR-124 inhibits cell proliferation in gastric cancer through down-regulation of SPHK1. J Pathol. 2012;227:470\u201380.","journal-title":"J Pathol"},{"key":"746_CR20","doi-asserted-by":"publisher","first-page":"1346","DOI":"10.3892\/or.2012.1958","volume":"28","author":"Y Sun","year":"2012","unstructured":"Sun Y, Zhao X, Zhou Y, Hu Y. miR-124, miR-137 and miR-340 regulate colorectal cancer growth via inhibition of the Warburg effect. Oncol Rep. 2012;28:1346\u201352.","journal-title":"Oncol Rep"},{"key":"746_CR21","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1038\/onc.2012.598","volume":"33","author":"P Wang","year":"2014","unstructured":"Wang P, Chen L, Zhang J, Chen H, Fan J, Wang K, et al. Methylation-mediated silencing of the miR-124 genes facilitates pancreatic cancer progression and metastasis by targeting Rac1. Oncogene. 2014;33:514\u201324.","journal-title":"Oncogene"},{"key":"746_CR22","doi-asserted-by":"publisher","first-page":"4130","DOI":"10.1038\/onc.2012.425","volume":"32","author":"XB Shi","year":"2013","unstructured":"Shi XB, Xue L, Ma AH, Tepper CG, Gandour-Edwards R, Kung HJ, et al. Tumor suppressive miR-124 targets androgen receptor and inhibits proliferation of prostate cancer cells. Oncogene. 2013;32:4130\u20138.","journal-title":"Oncogene"},{"key":"746_CR23","doi-asserted-by":"publisher","first-page":"821","DOI":"10.5732\/cjc.011.10289","volume":"30","author":"XB Lv","year":"2011","unstructured":"Lv XB, Jiao Y, Qing Y, Hu H, Cui X, Lin T, et al. miR-124 suppresses multiple steps of breast cancer metastasis by targeting a cohort of pro-metastatic genes in vitro. Chin J Cancer. 2011;30:821\u201330.","journal-title":"Chin J Cancer"},{"key":"746_CR24","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1093\/carcin\/bgs383","volume":"34","author":"YJ Liang","year":"2013","unstructured":"Liang YJ, Wang QY, Zhou CX, Yin QQ, He M, Yu XT, et al. MiR-124 targets slug to regulate epithelial-mesenchymal transition and metastasis of breast cancer. Carcinogenesis. 2013;34:713\u201322.","journal-title":"Carcinogenesis"},{"key":"746_CR25","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1159\/000350100","volume":"31","author":"ZB Han","year":"2013","unstructured":"Han ZB, Yang Z, Chi Y, Zhang L, Wang Y, Ji Y, et al. MicroRNA-124 suppresses breast cancer cell growth and motility by targeting CD151. Cell Physiol Biochem. 2013;31:823\u201332.","journal-title":"Cell Physiol Biochem"},{"key":"746_CR26","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1186\/1476-4598-12-163","volume":"12","author":"L Li","year":"2013","unstructured":"Li L, Luo J, Wang B, Wang D, Xie X, Yuan L, et al. Microrna-124 targets flotillin-1 to regulate proliferation and migration in breast cancer. Mol Cancer. 2013;12:163.","journal-title":"Mol Cancer"},{"key":"746_CR27","doi-asserted-by":"crossref","first-page":"16205","DOI":"10.18632\/oncotarget.7578","volume":"7","author":"T Feng","year":"2016","unstructured":"Feng T, Shao F, Wu Q, Zhang X, Xu D, Qian K, et al. miR-124 downregulation leads to breast cancer progression via LncRNA-MALAT1 regulation and CDK4\/E2F1 signal activation. Oncotarget. 2016;7:16205\u201316.","journal-title":"Oncotarget"},{"key":"746_CR28","first-page":"1139","volume":"62","author":"F Zhang","year":"2016","unstructured":"Zhang F, Wang B, Long H, Yu J, Li F, Hou H, et al. Decreased miR-124-3p expression prompted breast cancer cell progression mainly by targeting Beclin-1. Clin Lab. 2016;62:1139\u201345.","journal-title":"Clin Lab"},{"key":"746_CR29","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1186\/s13000-015-0257-5","volume":"10","author":"LL Dong","year":"2015","unstructured":"Dong LL, Chen LM, Wang WM, Zhang LM. Decreased expression of microRNA-124 is an independent unfavorable prognostic factor for patients with breast cancer. Diagn Pathol. 2015;10:45.","journal-title":"Diagn Pathol"},{"key":"746_CR30","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1002\/jcb.22556","volume":"110","author":"PK Ng","year":"2010","unstructured":"Ng PK, Tsui SK, Lau CP, Wong CH, Wong WH, Huang L, et al. CCAAT\/enhancer binding protein beta is up-regulated in giant cell tumor of bone and regulates RANKL expression. J Cell Biochem. 2010;110:438\u201346.","journal-title":"J Cell Biochem"},{"key":"746_CR31","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1016\/j.bone.2014.06.021","volume":"66","author":"W Zhou","year":"2014","unstructured":"Zhou W, Yin H, Wang T, Liu T, Li Z, Yan W, et al. MiR-126-5p regulates osteolysis formation and stromal cell proliferation in giant cell tumor through inhibition of PTHrP. Bone. 2014;66:267\u201376.","journal-title":"Bone"},{"key":"746_CR32","doi-asserted-by":"publisher","first-page":"406","DOI":"10.4161\/rna.23543","volume":"10","author":"AK Hollensen","year":"2013","unstructured":"Hollensen AK, Bak RO, Haslund D, Mikkelsen JG. Suppression of microRNAs by dual-targeting and clustered tough decoy inhibitors. RNA Biol. 2013;10:406\u201314.","journal-title":"RNA Biol"},{"key":"746_CR33","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/0378-1119(89)90358-2","volume":"77","author":"SN Ho","year":"1989","unstructured":"Ho SN, Hunt HD, Horton RM, Pullen JK, Pease LR. Site-directed mutagenesis by overlap extension using the polymerase chain reaction. Gene. 1989;77:51\u20139.","journal-title":"Gene"},{"key":"746_CR34","doi-asserted-by":"publisher","first-page":"e0159891","DOI":"10.1371\/journal.pone.0159891","volume":"11","author":"YH Joung","year":"2016","unstructured":"Joung YH, Darvin P, Kang DY, Sp N, Byun HJ, Lee CH, et al. Methylsulfonylmethane inhibits RANKL-induced osteoclastogenesis in BMMs by suppressing NF-\u03baB and STAT3 activities. PLoS One. 2016;11:e0159891.","journal-title":"PLoS One"},{"key":"746_CR35","doi-asserted-by":"publisher","first-page":"R105","DOI":"10.1186\/bcr3047","volume":"13","author":"E Pivetta","year":"2011","unstructured":"Pivetta E, Scapolan M, Pecolo M, Wassermann B, Abu-Rumeileh I, Balestreri L, et al. MMP-13 stimulates osteoclast differentiation and activation in tumour breast bone metastases. Breast Cancer Res. 2011;13:R105.","journal-title":"Breast Cancer Res"},{"key":"746_CR36","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1016\/j.bone.2013.07.007","volume":"56","author":"Y Lee","year":"2013","unstructured":"Lee Y, Kim HJ, Park CK, Kim YG, Lee HJ, Kim JY, et al. MicroRNA-124 regulates osteoclast differentiation. Bone. 2013;56:383\u20139.","journal-title":"Bone"},{"key":"746_CR37","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1016\/j.bone.2016.04.006","volume":"87","author":"A Irelli","year":"2016","unstructured":"Irelli A, Cocciolone V, Cannita K, Zugaro L, Di Staso M, Lanfiuti Baldi P, et al. Bone targeted therapy for preventing skeletal-related events in metastatic breast cancer. Bone. 2016;87:169\u201375.","journal-title":"Bone"},{"key":"746_CR38","doi-asserted-by":"crossref","unstructured":"Early Breast Cancer Trialists' Collaborative Group (EBCTCG), Coleman R, Powles T, Paterson A, Gnant M, Anderson S, et al. Adjuvant bisphosphonate treatment in early breast cancer: meta-analyses of individual patient data from randomised trials. Lancet. 2015;386:1353\u20131361.","DOI":"10.1016\/S0140-6736(15)60908-4"},{"key":"746_CR39","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1093\/annonc\/mdv617","volume":"27","author":"P Hadji","year":"2016","unstructured":"Hadji P, Coleman RE, Wilson C, Powles TJ, Cl\u00e9zardin P, Aapro M, et al. Adjuvant bisphosphonates in early breast cancer: consensus guidance for clinical practice from a European panel. Ann Oncol. 2016;27:379\u201390.","journal-title":"Ann Oncol"},{"key":"746_CR40","doi-asserted-by":"publisher","first-page":"1516","DOI":"10.1172\/JCI117130","volume":"93","author":"G Girasole","year":"1994","unstructured":"Girasole G, Passeri G, Jilka RL, Manolagas SC. Interleukin-11: a new cytokine critical for osteoclast development. J Clin Invest. 1994;93:1516\u201324.","journal-title":"J Clin Invest"},{"key":"746_CR41","doi-asserted-by":"publisher","first-page":"63S","DOI":"10.1016\/8756-3282(95)00180-L","volume":"17","author":"SC Manolagas","year":"1995","unstructured":"Manolagas SC. Role of cytokines in bone resorption. Bone. 1995;17:63S\u20137S.","journal-title":"Bone"},{"key":"746_CR42","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1007\/s001980070028","volume":"11","author":"JE Aubin","year":"2000","unstructured":"Aubin JE, Bonnelye E. Osteoprotegerin and its ligand: a new paradigm for regulation of osteoclastogenesis and bone resorption. Osteoporos Int. 2000;11:905\u201313.","journal-title":"Osteoporos Int"},{"key":"746_CR43","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/S8756-3282(02)00915-8","volume":"32","author":"O Kudo","year":"2003","unstructured":"Kudo O, Sabokbar A, Pocock A, Itonaga I, Fujikawa Y, Athanasou NA. Interleukin-6 and interleukin-11 support human osteoclast formation by a RANKL-independent mechanism. Bone. 2003;32:1\u20137.","journal-title":"Bone"},{"key":"746_CR44","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/S0304-3835(01)00524-9","volume":"169","author":"C Sotiriou","year":"2001","unstructured":"Sotiriou C, Lacroix M, Lespagnard L, Larsimont D, Paesmans M, Body JJ. Interleukins-6 and \u221211 expression in primary breast cancer and subsequent development of bone metastases. Cancer Lett. 2001;169:87\u201395.","journal-title":"Cancer Lett"},{"key":"746_CR45","doi-asserted-by":"publisher","first-page":"802","DOI":"10.1245\/ASO.2006.05.028","volume":"13","author":"S Hanavadi","year":"2006","unstructured":"Hanavadi S, Martin TA, Watkins G, Mansel RE, Jiang WG. Expression of interleukin 11 and its receptor and their prognostic value in human breast cancer. Ann Surg Oncol. 2006;13:802\u20138.","journal-title":"Ann Surg Oncol"},{"key":"746_CR46","doi-asserted-by":"publisher","first-page":"736","DOI":"10.1093\/jnci\/djp082","volume":"101","author":"MC Cheang","year":"2009","unstructured":"Cheang MC, Chia SK, Voduc D, Gao D, Leung S, Snider J, et al. Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer. J Natl Cancer Inst. 2009;101:736\u201350.","journal-title":"J Natl Cancer Inst"}],"updated-by":[{"DOI":"10.1186\/s12943-020-01226-1","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2020,6,27]],"date-time":"2020-06-27T00:00:00Z","timestamp":1593216000000}}],"container-title":["Molecular Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12943-017-0746-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12943-017-0746-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12943-017-0746-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,30]],"date-time":"2024-06-30T15:20:12Z","timestamp":1719760812000},"score":1,"resource":{"primary":{"URL":"https:\/\/molecular-cancer.biomedcentral.com\/articles\/10.1186\/s12943-017-0746-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,1,17]]},"references-count":46,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["746"],"URL":"https:\/\/doi.org\/10.1186\/s12943-017-0746-0","relation":{"correction":[{"id-type":"doi","id":"10.1186\/s12943-020-01226-1","asserted-by":"object"}]},"ISSN":["1476-4598"],"issn-type":[{"value":"1476-4598","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,1,17]]},"assertion":[{"value":"15 June 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 November 2017","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 January 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 June 2020","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"An amendment to this paper has been published and can be accessed via the original article.","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"All of the clinical subjects provided written informed consent. Ethical consent was granted by the Committees for Ethical Review of Research involving Human Subjects of Second Military Medical University (Shanghai, China). All of the mouse experiments were performed according to protocols reviewed and approved by the Institutional Animal Care and Use Committee at the Second Military Medical University.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"9"}}